Morepen LaboratoriesQ4 FY24

Morepen Laboratories Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹94.66P/E: 27.5Market Cap: ₹5.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Medical Devices segment is the fastest-growing business at 28% CAGR; overall company CAGR is 16%.
  • Planned meter sales: 30 lakh meters this year, increasing to 36 lakh and then 40 lakh meters in subsequent years.
  • Strips per meter sold currently ~150, aiming to increase to 155+ (was 165 during COVID due to high usage).
  • Addressable market for meters estimated at 5 crores; currently at 1 crore installed meters, targeting growth to 2-3 crores over 3-4 years.
  • Sales growth target: around 27% CAGR for meters to double in 3 years.
  • Revenues from Strips expected to grow proportionally with meters.
  • Capacity expansions underway with high-speed machines to meet increasing demand.
  • API business revenue grew 14% annually; U.S. market grew 32% recently.
  • Formulation & OTC businesses aim for breakeven with moderate growth (~10%).
  • Overall company revenue expected to maintain 20% growth, with EBITDA and margins improving alongside volume growth.

See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There are no current plans for fundraising through debt or equity mentioned.
  • The company is working on regulatory procedures related to the medical devices business but has not planned any capital event yet.
  • Fundraising or capital raising for the medical devices segment may happen in the future at an appropriate stage, but no concrete plans are on the card currently.
  • The company emphasizes internal accruals and aims to expand capacity and backward integration using internal resources.
  • They are a largely debt-free company with negligible debt and have cleared all old debts.
  • Any future capital-raising for the devices business will depend on business needs and regulatory approvals.

See what Morepen Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is actively expanding capacities, especially in medical devices and APIs, due to increasing demand.
  • Major part of capex is directed toward building large sheds to accommodate injection molding and other machinery for backward integration in medical devices.
  • High-speed machines with higher capacities have been installed in formulation to improve volume and profitability.
  • Research and development investments include three labs: Okhla (biosensors), Baddi (in-house medical device production), and Bangalore (electronics).
  • Existing gross block investments mainly cater to API and formulation, with potential to increase topline by approximately Rs. 150-200 crores in API and 2.5-3 times in formulation over the next 1-2 years without major new CAPEX.
  • The company plans to start shifting medical devices business into a separate company within the financial year, which may involve new licenses and potential capital events or fundraising.
  • Investments are funded through internal accruals; the company remains largely debt-free.

Track Morepen Laboratories — get its next earnings analysis in your feed

How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisMorepen Laboratories
Rev 2Mar 1

How does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →